Circuit Therapeutics was a pioneering biotechnology company focused on developing novel therapies for neurological and psychiatric diseases using optogenetics, a cutting-edge technology that employs light to control nerve cells with high precision. Founded in 2010, the company aimed to translate advanced neuroscience research into targeted and effective treatments for conditions with significant unmet medical needs. In July 2021, Circuit Therapeutics was acquired by Merck & Co., Inc. (known as MSD outside the United States and Canada), with the goal of integrating Circuit's innovative neuromodulation platform into Merck's broader research and development efforts in neuroscience.
The headquarters served as the primary center for its research and development activities in optogenetic therapies, including laboratory experiments, preclinical studies, and corporate operations.
The facility likely housed advanced neuroscience research laboratories equipped for optogenetics, cell biology, and molecular biology, along with collaborative office spaces designed to foster innovation among its scientific and operational teams.
As a venture-backed biotech startup, the work culture at Circuit Therapeutics was likely characterized by a fast-paced, innovative, and scientifically rigorous environment. Emphasis would have been on collaboration, problem-solving, and a shared mission to advance treatments for debilitating neurological disorders.
The Menlo Park headquarters was central to Circuit Therapeutics' identity and operations, enabling it to tap into the rich talent pool, academic collaborations, and investment opportunities available in the San Francisco Bay Area's biotech ecosystem.
Before its acquisition by Merck, Circuit Therapeutics' global engagement was primarily through its research collaborations, potential partnerships with international academic institutions, and participation in the global neuroscience community. Its direct operational footprint was centered in the United States. Following the acquisition, its technology and programs became part of Merck's extensive global research and development network.
1505 Adams Drive, Suite B1
Menlo Park
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Circuit Therapeutics' leadership includes:
Circuit Therapeutics has been backed by several prominent investors over the years, including:
Circuit Therapeutics was acquired by Merck in July 2021. As a result, there have been no executive hires or exits attributable to Circuit Therapeutics as an independent operational entity within the last 12 months from the current date. All leadership roles and structures were resolved as part of the acquisition process.
Discover the tools Circuit Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition, Circuit Therapeutics likely used standard corporate email formats common in the biotech industry. Based on typical conventions, the primary format was probably [first_initial][last]@circuittherapeutics.com or [first].[last]@circuittherapeutics.com. Note: As the company domain is no longer active, these email addresses are not functional.
flast@circuittherapeutics.com (e.g., jdoe@circuittherapeutics.com)
Format
dshnell@circuittherapeutics.com
Example
70%
Success rate
Merck.com • July 12, 2021
Merck announced its acquisition of Circuit Therapeutics, a company specializing in optogenetics to develop new medicines for neurological diseases. The acquisition is intended to enhance Merck's capabilities in neuroscience and leverage Circuit's proprietary technology platform for novel target discovery and precision neuromodulation therapies....more
FierceBiotech • July 19, 2016
Circuit Therapeutics secured $17 million in a Series A extension financing round. Key investors included GV (formerly Google Ventures) and Roche Venture Fund. The funds were designated to advance the company's optogenetics platform for treating neurological and psychiatric disorders by enabling precise control over neural circuits....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Circuit Therapeutics, are just a search away.